IXICO signs its first contract with a new biopharma customer to deploy biosensors in a late stage clinical trial for a psychiatric disorder
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, announces that it has signed a new contract with another leading biopharmaceutical company to support the use of wrist worn activity sensors (‘wearable biosensors’) in a late stage trial for a psychiatric disorder.
This contract with a new biopharma customer has a value c. £0.75m over a two year term, commencing in November 2017. IXICO will utilise its biosensor capabilities, combined with its artificial intelligence data analytics algorithms, to measure sleep, day time napping, overall daily activity levels and patterns using data collected from c.200 people at multiple time points. Furthermore, the study will allow the exploratory digital measures of patient quality of life to be evaluated alongside standard clinical measures.
Double-digit revenue growth Three new contracts signed in September, including first wearables contract IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today provides the following pre-close trading update ahead of its preliminary [...]
IXICO today announces that it has signed a new contract, with a top 15 global pharmaceutical company, utilising wrist worn activity sensors (‘wearable biosensors’) in a Phase II clinical trial for a neurological disorder. This is IXICO’s [...]
IXICO, the digital technologies company serving neuroscience, today announces that it has signed a new contract with a customer for its technology enabled imaging services. The contract value is US$690k over a two and a half year [...]
IXICO to provide specialist MR and PET imaging services in Phase II Huntington’s disease clinical trial
IXICO today announces that it has signed a new contract with a North American based biopharmaceutical company. The contract value is £1.2m over a three year term. IXICO will provide its technology enabled imaging services in [...]
IXICO announces an expansion of its pilot of the Assessa® PML platform which includes Biogen, a leading company in Multiple Sclerosis (“MS”), and expert reading institutions. The Assessa® PML digital platform is being piloted in five [...]
IXICO is today holding an Expert Symposium on the impact and future of imaging and digital biomarkers in Alzheimer’s disease. The symposium is set to coincide with the Alzheimer’s Association International Conference (AAIC) in London, UK. [...]